TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00471653
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00459446
Drug: MS-325 Injection (Gadofosveset Trisodium)
Normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03493295
Drug: Levonogestrel IntraUterine System (LNG-IUS)
Normalized name: levonorgestrel Intrauterine System
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the routine clinical practice. Jaydess, Mirena, Kyleena Or any other levonogestrel intrauterine system (LNG-IUS) commercialized in Spain at the start of the study, only for contraception indication.
Study: NCT02058706
Drug: leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo orchiectomy or receive LHRH analogue therapy
Study: NCT01665196
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
Study: NCT00003464
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01904409
Drug: Rifaximin SSD 40 mg IR tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01904409
Drug: Rifaximin SSD 80 mg IR tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01904409
Drug: Rifaximin SSD 40 mg SER tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01904409
Drug: Rifaximin SSD 80 mg SER tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01904409
Drug: Rifaximin SSD 80mgIR/80mgSER tablet
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00257348
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02058706
Drug: goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo orchiectomy or receive LHRH analogue therapy
Study: NCT03986996
Drug: amoxicillin and doxycyclin
Normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotics: Patient weight 30-50 kg Patient weight \> 50 kg Tetracycline 50 mg X 2 Day X 2 weeks 100 mg X 2 Day X 2 weeks Amoxicillin 750 mg X 2 Day X 2 weeks 750 mg X 2 Day X 2 weeks
Study: NCT03096340
Drug: IT-141
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
Study: NCT01308736
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
Study: NCT00590187
Drug: Sapacitabine, Arm A
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. x 7 days every 3-4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm B
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg b.i.d. x 7 days every 3 - 4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm C
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm D
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. x 7 consecutive days every 4 weeks
Study: NCT00590187
Drug: sapacitabine, Arm E
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg q.d. x 7 consecutive days every 4 weeks
Study: NCT00590187
Drug: sapacitabine, Arm F
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm G
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg b.i.d. x 7 consecutive days every 4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm H
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg q.d. x 7 consecutive days every 4 weeks
Study: NCT00590187
Drug: Sapacitabine, Arm I
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
Study: NCT00634439
Drug: atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00467740
Drug: BI 1744 CL
Normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00316537
Drug: ATG002 (study drug)
Normalized name: ethanol
DrugBank: ATG002 (DB05068)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01259817
Drug: PEGASYS
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
Study: NCT01259817
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 81 or 100 mg daily.
Study: NCT04350281
Drug: Interferon Beta-1B
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily subcutaneous injection of interferon β-1b 1mL (0.25mg; 8 million IU) consecutively on day 1 to day 3
Study: NCT04350281
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine 800mg on day 1, then 400mg daily for 2 days
Study: NCT03264274
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Antiangiogenic
Study: NCT01092728
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg daily.
Study: NCT04139226
Drug: CC-11050
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-11050
Study: NCT00259714
Drug: dialysate sodium individualization
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized).
Study: NCT01495208
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: intravitreal aflibercept injection 2mg
Study: NCT02650193
Drug: HSP-130
Normalized name: Autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene
DrugBank: Atidarsagene autotemcel (DB17538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
Study: NCT01167803
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients undergo anesthesia using remifentanil associated with desflurane
Study: NCT01167803
Drug: Xenon
Normalized name: xenon
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergo anesthesia using remifentanil associated with xenon
Study: NCT00371592
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg tablet taken orally twice daily
Study: NCT00371592
Drug: Acyclovir placebo
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg placebo tablet taken orally twice daily
Study: NCT02073123
Drug: Indoximod
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth~Dose escalation:~* If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled~* If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects~* If \> 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease~* If \>1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If \>1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed~Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity~Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1
Study: NCT00005952
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02073123
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
Study: NCT02073123
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered intravenously at 240 mg every 2 weeks.
Study: NCT02073123
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab administered intravenously at 2 mg/kg every three weeks.
Study: NCT00239434
Drug: tiotropium inhalation powder capsule
Normalized name: tiotropium Inhalation Powder
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00239434
Drug: ipratropium bromide Metered Dose Inhaler
Normalized name: ipratropium bromide Metered Dose Inhaler
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00131144
Drug: Octreotide Acetate in Microspheres 20 mg
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00131144
Drug: Octreotide Acetate in Microspheres
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02308553
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib (150 mg or 200 mg BID)
Study: NCT05065905
Drug: Interferon-Gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT00646646
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sedative
Study: NCT00646646
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sedative
Study: NCT00646646
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: sedative
Study: NCT02519439
Drug: ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 225 mg capsules 450 mg to 900 mg 2x/day
Study: NCT02308553
Drug: Nintedanib-Placebo
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo (150 mg or 200 mg BID)
Study: NCT00230126
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
Study: NCT00191412
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01149395
Drug: Dexlansoprazole
Normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage: 30 mg once per day for 4 weeks by mouth
Study: NCT02758717
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01377428
Drug: Indacaterol
Normalized name: Indacaterol
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
Study: NCT01377428
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
Study: NCT02308553
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
Study: NCT01067677
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 mg/kg (max 4 mg0
Study: NCT01067677
Drug: diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg/kg (max 25 mg)
Study: NCT01067677
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: equal volume (5 ml)as experimental rescue medications
Study: NCT02161796
Drug: FG-4592
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02014142
Drug: Latanoprost Punctal Plug Delivery System (L-PPDS)
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost Punctal Plug Delivery System (L-PPDS)
Study: NCT01551407
Drug: Hexvix
DrugBank: Hexaminolevulinate (DB06261)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
Study: NCT01234116
Drug: emtricitabine/tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each health care worker will receive one of the Treatment Arms for 28 days.
Study: NCT03901937
Drug: ω-3 polyunsaturated fatty acid
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD patients are divided into two groups, which include with and without ω-3 polyunsaturated fatty acid-based PN (0.1-0.2g/kg/d).
Study: NCT03797924
Drug: Receive ICBN with ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ICBN block will be performed using US guidance depositing 10 ml of 0.5% ropivacaine in the plane between pectoralis minor and serratus anterior over the 2nd and 3rd intercostal space.
Study: NCT00317577
Drug: brimonidine, timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04056039
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
Study: NCT04056039
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy of atorvastatin 40 mg orally every 24 hours for four weeks vs colchicine with an initial dose of 0.25 mg every 8 hours, with titration in the first 3 days according to tolerance up to a maximum dose of 0.5 mg every 8 hours for four weeks in decrease of troponin I of high sensitivity
Study: NCT01337635
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
Study: NCT02135042
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02135042
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02135042
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03900442
Drug: PTX-100
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses of 500 to 2000 mg/m2 will be administered.
Study: NCT00813449
Drug: dacarbazine plus Endostar (Experimental group)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dacarbazine plus Endostar
Study: NCT00813449
Drug: dacarbazine plus placebo (control group)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dacarbazine plus placebo
Study: NCT01406262
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01089751
Drug: trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
Study: NCT03990272
Drug: AIT drops
Normalized name: AIT-034
DrugBank: AIT-034 (DB06106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT00528957
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg. During the extension phase, participants whose weight increases to \> 37 kg may be switched from the oral powder to the tenofovir DF tablet.
Study: NCT00528957
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine as prescribed by the investigator prior to study entry (pediatric participants \< 30 kg: 1 mg/kg/dose given every 12 hours; pediatric participants ≥ 30 kg: 30 mg twice daily).
Study: NCT00528957
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine as prescribed by the investigator prior to study entry (pediatric participants 6 weeks to 12 years of age: 160 mg/m\^2 every 8 hours; pediatric participants \> 12 years of age: 300 mg twice daily).
Study: NCT05802290
Drug: Nivolumab 240 MG in 24 ML Injection
Normalized name: nivolumab 240 MG in 24 ML Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab monotherapy at 240mg flat dose as a 30-minute IV infusion on Day 1 of a treatment cycle every 2 weeks (14 days) until confirmed progression of disease, unacceptable toxicity, death or withdrawal of consent
Study: NCT00395616
Drug: Botox (drug)
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT03959241
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting on Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels per institutional guidelines with a suggested range of 5-15. If patients are on medications which alter the metabolism of tacrolimus (e.g.concurrent CYP3A4 inhibitors), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices and patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD.
Study: NCT00976131
Drug: CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules taken daily for two weeks prior to Cycle 3 chemotherapy infusion OR Capsules taken daily for two weeks prior to Cycle 4 infusion.~Dose Level 1: 300mg/d CoQ10 (2 capsules) Dose Level 2: 600mg/d CoQ10 (4 capsules) Dose Level 3: 1200mg/d CoQ10 (8 capsules)
Study: NCT03959241
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be given per institutional practices, orally at a dose of 0.05-0.06 mg/kg/day or intravenously at a dose of 0.02-0.03 mg/kg/day starting Day +5. Starting tacrolimus dose can be modified to account for possible drug interactions (e.g. concurrent CYP3A4 inhibitor use) according to institutional guides. Serum levels of tacrolimus will be measured at Day +7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HCT if there is no evidence of active GVHD
Study: NCT03959241
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF will be given at a dose of 15 mg/kg/dose ter in die (TID) (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day +5 and discontinue after the last dose on Day +35, or may be continued if active GVHD is present.
Study: NCT03593213
Drug: Cariprazine
Normalized name: Cariprazine
DrugBank: Cariprazine (DB06016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cariprazine capsules, oral administration, once daily.
Study: NCT01178632
Drug: Passiflora
Normalized name: Passiflora incarnata
DrugBank: Passiflora incarnata flower (DB13974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 tablet Passiflora p.o., b.i.d.